961 related articles for article (PubMed ID: 25341935)
1. Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.
Gilabert-Oriol R; Weng A; Mallinckrodt Bv; Melzig MF; Fuchs H; Thakur M
Curr Pharm Des; 2014; 20(42):6584-643. PubMed ID: 25341935
[TBL] [Abstract][Full Text] [Related]
2. Ribosome-Inactivating Proteins from Plants: A Historical Overview.
Bolognesi A; Bortolotti M; Maiello S; Battelli MG; Polito L
Molecules; 2016 Nov; 21(12):. PubMed ID: 27898041
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in research on ribosome inactivating proteins.
Ng TB; Wong JH; Wang H
Curr Protein Pept Sci; 2010 Feb; 11(1):37-53. PubMed ID: 20201806
[TBL] [Abstract][Full Text] [Related]
4. Dianthin and Its Potential in Targeted Tumor Therapies.
Fuchs H
Toxins (Basel); 2019 Oct; 11(10):. PubMed ID: 31614697
[TBL] [Abstract][Full Text] [Related]
5. The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations.
Rust A; Partridge LJ; Davletov B; Hautbergue GM
Toxins (Basel); 2017 Oct; 9(11):. PubMed ID: 29076988
[TBL] [Abstract][Full Text] [Related]
6. Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy.
Ferreras JM; Citores L; Iglesias R; Jiménez P; Girbés T
Toxins (Basel); 2011 May; 3(5):420-41. PubMed ID: 22069717
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.
Polito L; Bortolotti M; Pedrazzi M; Bolognesi A
Toxins (Basel); 2011 Jun; 3(6):697-720. PubMed ID: 22069735
[TBL] [Abstract][Full Text] [Related]
8. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins.
Preijers FW
Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066
[TBL] [Abstract][Full Text] [Related]
9. Ribosome-inactivating and related proteins.
Schrot J; Weng A; Melzig MF
Toxins (Basel); 2015 May; 7(5):1556-615. PubMed ID: 26008228
[TBL] [Abstract][Full Text] [Related]
10. [Highly toxic type Ⅱ ribosome-inactivating proteins ricin and abrin and their detection methods: a review].
Liang L; Xia J; Liu C; Liu S
Se Pu; 2021 Mar; 39(3):260-270. PubMed ID: 34227307
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.
Giansanti F; Flavell DJ; Angelucci F; Fabbrini MS; Ippoliti R
Toxins (Basel); 2018 Feb; 10(2):. PubMed ID: 29438358
[TBL] [Abstract][Full Text] [Related]
12. Ribosome-inactivating proteins: from plant defense to tumor attack.
de Virgilio M; Lombardi A; Caliandro R; Fabbrini MS
Toxins (Basel); 2010 Nov; 2(11):2699-737. PubMed ID: 22069572
[TBL] [Abstract][Full Text] [Related]
13. A new age for biomedical applications of Ribosome Inactivating Proteins (RIPs): from bioconjugate to nanoconstructs.
Pizzo E; Di Maro A
J Biomed Sci; 2016 Jul; 23(1):54. PubMed ID: 27439918
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the uses and applications of ribosome-inactivating proteins from plants.
Girbés T; Ferreras JM; Iglesias R; Citores L; De Torre C; Carbajales ML; Jiménez P; De Benito FM; Muñoz R
Cell Mol Biol (Noisy-le-grand); 1996 Jun; 42(4):461-71. PubMed ID: 8828901
[TBL] [Abstract][Full Text] [Related]
15. A novel adenine-releasing assay for ribosome-inactivating proteins.
Weng A
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():300-304. PubMed ID: 29202361
[TBL] [Abstract][Full Text] [Related]
16. Improved Protein Toxin Delivery Based on ATTEMPTS Systems.
Chen Y; Zhang M; Min KA; Wang H; Shin MC; Li F; Yang VC; Huang Y
Curr Drug Targets; 2018 Feb; 19(4):380-392. PubMed ID: 28260497
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
18. Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression.
Gilabert-Oriol R; Thakur M; Weise C; Dernedde J; von Mallinckrodt B; Fuchs H; Weng A
Protein Expr Purif; 2013 Sep; 91(1):54-60. PubMed ID: 23867360
[TBL] [Abstract][Full Text] [Related]
19. New ribosome-inactivating proteins and other proteins with protein synthesis-inhibiting activities.
Wong JH; Bao H; Ng TB; Chan HHL; Ng CCW; Man GCW; Wang H; Guan S; Zhao S; Fang EF; Rolka K; Liu Q; Li C; Sha O; Xia L
Appl Microbiol Biotechnol; 2020 May; 104(10):4211-4226. PubMed ID: 32193575
[TBL] [Abstract][Full Text] [Related]
20. Production of anti-cancer immunotoxins in algae: ribosome inactivating proteins as fusion partners.
Tran M; Henry RE; Siefker D; Van C; Newkirk G; Kim J; Bui J; Mayfield SP
Biotechnol Bioeng; 2013 Nov; 110(11):2826-35. PubMed ID: 23719862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
